ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-08

Reporting Person: Piazza Jonathan (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-08	Common Stock	P	11904	$21.00	Acquired	11904	Direct

Footnotes

F1: The shares were purchased in the Issuer's initial public offering.